Clinical Trials
666
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (511 trials with phase data)β’ Click on a phase to view related trials
At-Home Transcutaneous Tibial Nerve Stimulation for Overactive Bladder in Rural Women
- Conditions
- Overactive Bladder
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 38
- Registration Number
- NCT07178314
- Locations
- πΊπΈ
Oregon Health & Science University, Portland, Oregon, United States
Rocklatan Retinal Perfusion OCT Study
- Conditions
- Glaucoma
- Interventions
- Drug: Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.Device: Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 30
- Registration Number
- NCT07174401
- Locations
- πΊπΈ
Casey Eye Institute - Oregon Health & Science University, Portland, Oregon, United States
Placental Risk Assessment to CusTomize Individualized Pregnancy Care and Evaluation
- Conditions
- StillbirthPlacental Insufficiency
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 640
- Registration Number
- NCT07144839
- Locations
- πΊπΈ
Oregon Health & Science University, Portland, Oregon, United States
Physical Therapy After Endometriosis Excision
- Conditions
- EndometriosisSurgery
- First Posted Date
- 2025-08-17
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 30
- Registration Number
- NCT07127783
- Locations
- πΊπΈ
Oregon Health & Science University, Portland, Oregon, United States
Insights in Endocervical Mucus Secretion
- Conditions
- Cervical Mucus
- Interventions
- Drug: Gonadotropin Releasing Hormone Antagonists Relugolix
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 15
- Registration Number
- NCT07111247
- Locations
- πΊπΈ
Oregon Health & Science University, Portland, Oregon, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 134
- Next
News
Oregon Study Demonstrates Psilocybin Therapy Efficacy for Low-Income Adults with Major Depression
A first-of-its-kind study by OHSU and National University of Natural Medicine found that low-income adults with major depressive disorder experienced significant depression reduction following group psilocybin therapy sessions.
Study Identifies Why Venetoclax-Based AML Treatment Fails in Certain Patients
Researchers analyzed 678 AML patients and found that both gene mutations and leukemia cell maturity affect response to venetoclax plus hypomethylating agents treatment.
Precede Biosciences Unveils Breakthrough Liquid Biopsy Platform for Tumor Gene Expression at AACR 2025
Precede Biosciences has developed a comprehensive epigenomic liquid biopsy platform capable of predicting expression of over 2,500 tumor-specific genes from just 1mL of blood plasma.
OB/GYN Workforce Shifts Following Abortion Bans: New Study Reveals Complex Migration Patterns
A new JAMA Network Open study reveals that while most OB/GYNs didn't immediately leave states with abortion bans after the 2022 Dobbs ruling, a significant decline is now occurring in the 12 most restrictive states.
Cancer Drug Use Rapidly Declines Following Withdrawal of FDA Accelerated Approval
A new study reveals significant decreases in oncology medication use after negative confirmatory trials are published, despite drugs remaining available for other indications.
NIH Launches CARE for Health Network to Enhance Primary Care Research
The NIH is investing $30 million to launch the CARE for Health network, aimed at integrating clinical research with community-based primary care.